DM and pharma companies

Abstract

A s mentioned in a previous feature article,* disease management (DM) may become the dominant strategy for healthcare delivery in the US. And a number of other countries are exploring DM strategies, including the UK. While ongoing structural reforms in the UK National Health Service (NHS) provide new opportunities for DM, a recent report suggests there are several hurdles to overcome before the approach is widely adopted - not least a pervasive culture of suspicion within the NHS towards the pharmaceutical industry.